Improving quality of care in inflammatory bowel disease: What changes can be made today?

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 919-926

  Panés, Julián ^a   O'Connor, Marian ^b   Peyrin Biroulet, Laurent ^c   Irving, Peter ^d   Petersson, Joel ^e   Colombel, Jean Frédéric ^f  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b ST MARK S HOSPITAL   (United Kingdom)

^c UNIVERSITÉ DE LORRAINE   (France)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e ABBVIE INC   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn disease; IBD centres of excellence; Inflammatory bowel diseases; Multidisciplinary team; Quality of care; Ulcerative colitis

Indexed keywords

DISEASE COURSE; DOCTOR PATIENT RELATION; EARLY DIAGNOSIS; EARLY INTERVENTION; EMPOWERMENT; EVIDENCE BASED PRACTICE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SELF CARE; TELECONSULTATION; INFLAMMATORY BOWEL DISEASES; PROCEDURES; TOTAL QUALITY MANAGEMENT; TRENDS; HEALTH CARE DELIVERY;

HUMANS; INFLAMMATORY BOWEL DISEASES; QUALITY ASSURANCE, HEALTH CARE; QUALITY IMPROVEMENT;

EID: 84906789688     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.02.022     Document Type: Review

References (42)

1. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
2. Jess T., Frisch M., Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013, 11:43-48.
3. Hoivik M.L., Moum B., Solberg I.C., Henriksen M., Cvancarova M., Bernklev T., et al. Work disability in inflammatory bowel disease patients 10years after disease onset: results from the IBSEN Study. Gut 2013, 62:368-375.
4. Wilson B., Lonnfors S., Hommes D.W., Vermiere S., Greco M., Bell C., et al. A European Crohn's and ulcerative colitis patient life IMPACT survey. Eighth Congress of the European Crohn's and Colitis Organisation 2013, [Abstract P406. Available at: https://www.ecco-ibd.eu/publications/congress-abstract-s/item/p06-a-euro.html].
5. Vienne A., Simon T., Cosnes J., Baudry C., Bouhnik Y., Soule J.C., et al. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. Aliment Pharmacol Ther 2011, 34:188-195.
6. Tinsley A., Naymagon S., Trindade A.J., Sachar D.B., Sands B.E., Ullman T.A. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013, 47:e1-e6.
7. Bouguen G., Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk?. Gut 2011, 60:1178-1181.
8. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
9. Schoepfer A.M., Dehlavi M.A., Fournier N., Safroneeva E., Straumann A., Pittet V., et al. IBD Cohort Study Group. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 2013, 108:1744-1753.
10. Solberg I.C., Lygren I., Jahnsen J., Vatn M.H., Moum B. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut 2008, 57. [Abstract A15].
11. Schreiber S., Reinisch W., Colombel J.F., Sandborn W.J., Hommes D.W., Robinson A.M., et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013, 7:213-221.
12. Jurgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427.
13. Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
14. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
15. Rutgeerts P., Vermeire S., Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010, 59:7-8.
16. Ben-Horin S., Yavzori M., Katz L., Kopylov U., Picard O., Fudim E., et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011, 60:41-48.
17. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
18. Ricci C., Lanzarotto F., Lanzini A. The multidisciplinary team for management of inflammatory bowel diseases. Dig Liver Dis 2008, 40(Suppl. 2):S285-S288.
19. Mawdsley J.E., Irving P.M., Makins R.J., Rampton D.S. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol 2006, 18:249-253.
20. Kaplan G.G., McCarthy E.P., Ayanian J.Z., Korzenik J., Hodin R., Sands B.E. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008, 134:680-687.
21. Whayman K. Supporting and educating patients. Inflammatory bowel disease nursing 2011, 333-357. MA Healthcare Ltd, London. K. Whayman, J. Duncan, M. O'Connor (Eds.).
22. O'Connor M. Criteria for success using an inflammatory bowel disease nurse telephone service. Gastrointest Nurs 2011, 9:35-40.
23. Irving P. The future developments in inflammatory bowel disease care. Frontline Gastroenterol 2012, 3:i42-i46.
24. Horne R., Cooper V., Gellaitry G., Date H.L., Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007, 45:334-341.
25. Horne R., Parham R., Driscoll R., Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:837-844.
26. Bokemeyer B., Teml A., Roggel C., Hartmann P., Fischer C., Schaeffeler E., et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007, 26:217-225.
27. Mantzaris G.J., Roussos A., Kalantzis C., Koilakou S., Raptis N., Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?. Inflamm Bowel Dis 2007, 13:446-450.
28. Lopez A., Billioud V., Peyrin-Biroulet C., Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013, 19:1528-1533.
29. McHorney C.A., Spain C.V. Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008. Health Expect 2011, 14:307-320.
30. National Institute for Health and Clinical Excellence Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. NICE clinical guideline 2009, 76. National Institute for Health and Clinical Excellence, Manchester.
31. Zolnierek K.B., Dimatteo M.R. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009, 47:826-834.
32. Miller W.R., Rollnick S. Motivational interviewing: helping people change 2013, Guilford Press, New York, NY. Third ed.
33. Johnson F.R., Ozdemir S., Mansfield C., Hass S., Miller D.W., Siegel C.A., et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007, 133:769-779.
34. Malenka D.J., Baron J.A., Johansen S., Wahrenberger J.W., Ross J.M. The framing effect of relative and absolute risk. J Gen Intern Med 1993, 8:543-548.
35. Garcia-Retamero R., Okan Y., Cokely E.T. Using visual aids to improve communication of risks about health: a review. Sci World J 2012, 2012:562637.
36. Siegel C.A., Siegel L.S., Hyams J.S., Kugathasan S., Markowitz J., Rosh J.R., et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011, 17:30-38.
37. Galesic M., Garcia-Retamero R., Gigerenzer G. Using icon arrays to communicate medical risks: overcoming low numeracy. Health Psychol 2009, 28:210-216.
38. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61:918-932.
39. Baars J.E., Markus T., Kuipers E.J., van der Woude C.J. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010, 81:113-119.
40. Elkjaer M., Shuhaibar M., Burisch J., Bailey Y., Scherfig H., Laugesen B., et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut 2010, 59:1652-1661.
41. World Health Organization Adherence to long-term therapies: evidence for action 2003, World Health Organization, Geneva.
42. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.